Checkpoint Blockade, Immune

DRUG2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Jules Bordet Institute

Conditions

Bladder CancerBreast CancerCutaneous MelanomaCutaneous Squamous Cell CarcinomaGastrointestinal CancerHead and Neck CancerHepatocellular CarcinomaMSI-H Colorectal Cancer

Early Phase 1

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Active, not recruitingNCT05358938

H. Lee Moffitt Cancer Center and Research InstituteCutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma

Start: 2022-06-21End: 2027-08-01Updated: 2026-09-15

Phase 2

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet InstituteBladder Cancer, Breast Cancer, Gastrointestinal Cancer +10

Start: 2022-09-01End: 2024-12-01Target: 441Updated: 2023-03-08

Related Papers

Physical activity and cancer biology: a narrative review of molecular mechanisms and introduction of the SCRUM-MONSTAR LIFELOG study.

2025-06-10

Abstract B035: Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

Cancer Immunology Research2025-02-23